A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
Condition(s)
Solid Tumor
Molecular Target(s)
TSC1, TSC2
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
NCT05503797
Phase(s)
II
Mechanism of Action
n/a
Purpose
n/a
Location
Mary Crowley Cancer Research - Medical City Dallas
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000